VEGFR酪氨酸激酶抑制剂II是同时具有抗血管生成和抗肿瘤特性的吡啶基蒽酰胺化合物。已显示该化合物有效抑制KDR，Flt-1和c-Kit的激酶活性（分别为IC | 50 | = 20 nM，180 nM和240 nM），并最小程度地抑制c-Src和EGF-R活性（IC | 50 | = 7 µM和7.3 µM）。VEGFR酪氨酸激酶抑制剂II对抑制CDK-1，c-Met，IGF-1R和PKA无效（IC | 50 |> 10 µM）。 VEGFR Tyrosine Kinase Inhibitor II is a pyridinyl-anthranilamide compound that displays both antiangiogenic and antitumor properties. The compound has been shown to potently inhibit the kinase activities of KDR, Flt-1 and c-Kit (IC|50|= 20 nM, 180 nM and 240 nM, respectively), and minimally inhibit c-Src and EGF-R activities (IC|50|= 7 μM and 7.3 μM). VEGFR Tyrosine Kinase Inhibitor II is inactive towards the inhibition of CDK-1, c-Met, IGF-1R and PKA (IC|50|> 10 μM).